Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Esco Lifesciences Raises $200 Million to Expand Life Science Tools Portfolio

publication date: May 27, 2021

Esco Lifesciences of Singapore, an Asia-based life sciences tools company, closed an over-subscribed $200 million Series A and crossover round. The financing will support strategic bolt-on M&A acquisitions and expedited expansion in China, the company's primary and fastest-growing market. Esco also intends to expand its cell and gene therapy tools and technologies portfolio, together with an innovation hub in Boston. The A round was led by Vivo Capital and Novo Holdings A/S. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital